Skip to main content
  • Contact Us
  • Vantage logo Sign Up
  • Subscriber Sign In
Evaluate Logo

navigation

  • What We Do
    • Commercial Intelligence
    • Products
      • Evaluate Pharma
      • Evaluate Omnium
      • Evaluate Medtech
      • Evaluate Epi
      • Japan Drug Forecasts
      • Europe Drug Forecasts
    • Pharma Consulting & Analytics
      • Pharma Consulting & Analytics
      • Data Feeds and APIs
    • Evaluate Vantage
      • News
      • Analysis
      • Policy & Pricing
      • Insights
      • Events
      • Medtech
      • Therapy Areas
      • Editorial Team
      • About Evaluate Vantage
    • Evaluate for Biotech
  • How We Can Help You
    • Pharma and Biotech
    • Financial Services
    • Management Consultancies
    • Service Providers
    • Customer Testimonials
  • Thought Leadership
    • Multimedia
    • Blog
  • About Us
    • Press Releases
    • Media Coverage
    • Executive Team
    • Vision & History
  • Contact Us
  • Sign Up for Evaluate Vantage
  • Talent
  • Subscriber Sign In

 

Vantage logo

Vantage

  • Covid-19
    • Covid-19 Coverage
    • Evaluate Vantage COVID-19 Report
  • News
    • Snippets
    • Deals
    • Trial results
    • Patents and litigation
    • Corporate strategy
  • Analysis
    • Interviews
    • Spotlight
    • Vantage points
    • Vantage views
  • Insights
    • M&A
    • IPO
    • NME approvals
    • Quarterly shareprice performance
    • Venture financing
    • Vantage data points
    • Other data
  • Events
    • Company events
    • Conferences
    • Upcoming events
  • Medtech
  • Therapy Areas
  • About
    • Editorial team

Breadcrumb

  1. Home
  2. Vantage
  3. Pharmaceutical Companies
  4. Oncopeptides
Thumbnail
January 12, 2022

Biopharma’s stock market winners of 2021 revealed

Lilly pips Pfizer to the big pharma top spot on share price performance, while Covid-19 drives the largest risers elsewhere.

Thumbnail
November 01, 2021

US FDA approval tracker: October 2021

Article image
Vantage logo
October 01, 2021

Go or no go? UCB bids to make a mark in psoriasis

Chemocentryx and Avadel will also see important FDA regulatory action this month, while Omeros gets another delay.

Article image
Vantage logo
September 29, 2021

Non-genetic amyloidosis lives again, thanks to Darzalex and Astra

Interest in AL amyloidosis has been piqued by January’s approval of Darzalex, and today Astrazeneca bought out a company with a phase 3 asset.

Article image
Vantage logo
September 13, 2021

End in sight for Oncopeptides’ stormy Ocean voyage

Pepaxto might not be a complete bust in myeloma.

Article image
Vantage logo
July 08, 2021

Oncopeptides gives with one hand and takes away with the other

Upon review Pepaxto beats Pomalyst on progression-free survival, but new overall survival data trigger clinical hold and threaten the programme.

Article image
Vantage logo
March 01, 2021

US FDA approval tracker February 2021

Article image
Vantage logo
January 27, 2021

Go or no go? Oncology decisions ahead for the FDA

The US regulator will provide verdicts on cancer projects from TG and Athenex, while Sarepta aims for its third Duchenne approval.

Article image
Vantage logo
June 05, 2019

Asco 2019 event analyser – low-key meeting belies some huge stock moves

Mirati Therapeutics nearly stole the show at Asco despite not actually presenting – a fact that illustrates how low on meaningful data this year's conference was.

Article image
Vantage logo
April 12, 2017

First-quarter floats see haves pulling away from the have-nots

Demand for new issues remains sluggish - only eight private biotechs managed to pull off an IPO in the first quarter of 2017.

We use cookies on this website. By using this site, you agree that we may store and access cookies on your device. Find out more.
Vantage logo
Independent, data-driven daily news and analysis on pharma, biotech and medtech.
Sign up

Latest Reports

July 28, 2022

Access Valuable Insights Payer Behaviour Infographic

July 18, 2022

Medtech - Going steady

View more...

Editor's Picks

Vantage logo
July 27, 2022

Aids 2022 preview – Gilead shoots for an HIV cure

Vantage logo
July 21, 2022

Private equity gets serious about drug development

Vantage logo
July 18, 2022

Unpacking Royalty Pharma

Vantage logo
July 19, 2022

No plain sailing for Novartis’s PD-1 plan

Vantage logo
July 26, 2022

Move over Aduhelm, it’s tofersen’s turn

Open modal

Evaluate Logo

Evaluate HQ
44-(0)20-7377-0800

Evaluate Americas
+1-617-573-9450

Evaluate APAC
+81-(0)70-4131-0112

Footer menu

  • Terms and conditions
  • Privacy Policies
  • Cookie Policy

© Copyright 2022 Evaluate Ltd.